International Assets Investment Management’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

International Assets Investment Management’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-19,701	Closed	-$240K	–	1230
2023 Q1	$240K	Buy	+19,701	New	+$441K	0.03%	425

Other funds holding GERM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

International Assets Investment Management's GERM Position: Q2 2023 in Review

International Assets Investment Management sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q2 2023, closing a stake of 19,701 shares — an estimated $240K sold.

International Assets Investment Management first reported a position in GERM in Q1 2023 and held it in 1 quarter. The position peaked at $240K in Q1 2023. 17 funds tracked by Wall St. Rank hold GERM as of Q2 2023.

International Assets Investment Management reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q2 2023 after selling out during the quarter.
International Assets Investment Management sold 19,701 Amplify Treatments, Testing and Advancements ETF shares in Q2 2023, an estimated $240K.
International Assets Investment Management first reported a position in Amplify Treatments, Testing and Advancements ETF in Q1 2023 and held it in 1 quarter.
International Assets Investment Management's Amplify Treatments, Testing and Advancements ETF position peaked at $240K in Q1 2023.
17 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q2 2023.

Based on International Assets Investment Management's 13F filing for Q2 2023, filed 20 Jul 2023.